{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:01Z","timestamp":1787020501897,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pharmalink International","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>NSAIDs are accepted as the most predictably efficacious medical treatment of the clinical signs of osteoarthritis (OA). The marine-based fatty-acid compound PCSO-524 has been proposed as an adjunctive treatment for canine OA, however benefits of this agent is still controversial. The purpose of this study was to evaluate and compare the effectiveness of PCSO-524 combined with the NSAID firocoxib using force plate gait analysis, orthopedic assessment score (OAS) and canine brief pain inventory score (CBPI) in dogs with OA.<\/jats:p>\n                    <jats:p>\n                      A prospective, randomized, double-blinded study was conducted. Seventy-nine dogs that had hip and\/or stifle OA were assigned randomly into three treatment groups: firocoxib, PCSO-524 and combination of firocoxib and PCSO-524, orally for 4\u2009weeks. Peak vertical force (PVF, expressed as a percentage of bodyweight), OAS, CBPI, serum prostaglandin E\n                      <jats:sub>2<\/jats:sub>\n                      concentration, hematology and blood chemistry values were evaluated before treatment (Day0), as well as at the second (Day14) and fourth week (Day28) during treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Within group analysis revealed significant increases in PVF over the 4-week treatment period for firocoxib, PCSO-524 and the combination (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Mean increases in PVF were 3.25\u2009\u00b1\u20094.13, 2.01\u2009\u00b1\u20093.86, 4.11\u2009\u00b1\u20094.69%BW (mean\u2009\u00b1\u2009SD) respectively. The OAS showed non-significant change in all treatment groups. There were significant decreases in CBPI pain severity score (PSS) and CBPI pain interference scores (PIS) within some groups over time, however no significant differences were found between the groups. Significantly decreased serum PGE\n                      <jats:sub>2<\/jats:sub>\n                      concentration (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) was found in the combination group. Significant increases in BUN and creatinine (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) compared to pre-treatment values were found in the firocoxib and combination groups but not in the PCSO-524 group at day28, but all values in all dogs remained within the normal ranges.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this study suggested combination of both PCSO-524 and firocoxib is more effective in alleviation of inflammation and improvement of weight bearing ability when compared to the uses of either PCSO-524 or firocoxib alone. Further clinical studies are needed to confirm this, and to determine if there is any benefit of PCSO-524 over placebo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12917-019-2110-7","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T11:25:14Z","timestamp":1571311514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Monchanok","family":"Vijarnsorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irin","family":"Kwananocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narudee","family":"Kashemsant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitichai","family":"Jarudecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalermpol","family":"Lekcharoensuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Peirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-9009","authenticated-orcid":false,"given":"B. Duncan X.","family":"Lascelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"issue":"4","key":"2110_CR1","first-page":"296","volume":"41","author":"PA Doig","year":"2000","unstructured":"Doig PA, Purbrick KA, Hare JE, McKeown DB. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J. 2000;41(4):296\u2013300.","journal-title":"Can Vet J"},{"issue":"11","key":"2110_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/vr.152.11.323","volume":"152","author":"M Moreau","year":"2003","unstructured":"Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. 2003;152(11):323\u20139.","journal-title":"Vet Rec"},{"issue":"11","key":"2110_CR3","first-page":"1057","volume":"55","author":"M Moreau","year":"2014","unstructured":"Moreau M, Lussier B, Ballaz L, Troncy E. Kinetic measurements of gait for osteoarthritis research in dogs and cats. Can Vet J. 2014;55(11):1057\u201365.","journal-title":"Can Vet J"},{"issue":"3","key":"2110_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0030-1248105","volume":"19","author":"BP Burnett","year":"2006","unstructured":"Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis. A review. J Knee Surg. 2006;19(3):191\u20137.","journal-title":"J Knee Surg"},{"issue":"6","key":"2110_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/j.pain.0000000000000521","volume":"157","author":"D Knazovicky","year":"2016","unstructured":"Knazovicky D, Helgeson ES, Case B, Gruen ME, Maixner W, Lascelles BD. Widespread somatosensory sensitivity in naturally occurring canine model of osteoarthritis. Pain. 2016;157(6):1325\u201332.","journal-title":"Pain"},{"issue":"9","key":"2110_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1292\/jvms.11-0529","volume":"74","author":"K Edamura","year":"2012","unstructured":"Edamura K, King JN, Seewald W, Sakakibara N, Okumura M. Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial. J Vet Med Sci. 2012;74(9):1121\u201331.","journal-title":"J Vet Med Sci"},{"issue":"14","key":"2110_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/vr.164.14.418","volume":"164","author":"RO Sanderson","year":"2009","unstructured":"Sanderson RO, Beata C, Flipo RM, Genevois JP, Macias C, Tacke S, Vezzoni A, Innes JF. Systematic review of the management of canine osteoarthritis. Vet Rec. 2009;164(14):418\u201324.","journal-title":"Vet Rec"},{"issue":"5","key":"2110_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/jvim.12127","volume":"27","author":"BP Monteiro-Steagall","year":"2013","unstructured":"Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med. 2013;27(5):1011\u20139.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2110_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1939-1676.2007.0014.x","volume":"22","author":"BD Lascelles","year":"2008","unstructured":"Lascelles BD, Gaynor JS, Smith ES, Roe SC, Marcellin-Little DJ, Davidson G, Boland E, Carr J. Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. J Vet Intern Med. 2008;22(1):53\u20139.","journal-title":"J Vet Intern Med"},{"key":"2110_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12970-015-0073-z","volume":"12","author":"TD Mickleborough","year":"2015","unstructured":"Mickleborough TD, Sinex JA, Platt D, Chapman RF, Hirt M. The effects PCSO-524(R), a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trial. J Int Soc Sports Nutr. 2015;12:10.","journal-title":"J Int Soc Sports Nutr"},{"issue":"4","key":"2110_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cbpb.2007.04.004","volume":"147","author":"AP Treschow","year":"2007","unstructured":"Treschow AP, Hodges LD, Wright PF, Wynne PM, Kalafatis N, Macrides TA. Novel anti-inflammatory omega-3 PUFAs from the New Zealand green-lipped mussel, Perna canaliculus. Comp Biochem Physiol B Biochem Mol Biol. 2007;147(4):645\u201356.","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"issue":"4","key":"2110_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11745-006-1394-0","volume":"40","author":"CJ Wolyniak","year":"2005","unstructured":"Wolyniak CJ, Brenna JT, Murphy KJ, Sinclair AJ. Gas chromatography-chemical ionization-mass spectrometric fatty acid analysis of a commercial supercritical carbon dioxide lipid extract from New Zealand green-lipped mussel (Perna canaliculus). Lipids. 2005;40(4):355\u201360.","journal-title":"Lipids"},{"issue":"3","key":"2110_CR13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.56808\/2985-1130.2750","volume":"46","author":"I Kwananocha","year":"2016","unstructured":"Kwananocha I, Vijarnsorn M, Kashemsant N, Lekcharoensuk C. Effectiveness of disease modifying osteoarthritis agents and carprofen for treatment of canine osteoarthritis. Thai J Vet Med. 2016;46(3):363\u201371.","journal-title":"Thai J Vet Med"},{"issue":"19","key":"2110_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/vr.104168","volume":"180","author":"ME Gruen","year":"2017","unstructured":"Gruen ME, Dorman DC, Lascelles BDX. Caregiver placebo effect in analgesic clinical trials for cats with naturally occurring degenerative joint disease-associated pain. Vet Rec. 2017;180(19):473.","journal-title":"Vet Rec"},{"issue":"1","key":"2110_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jvim.12004","volume":"27","author":"DC Brown","year":"2013","unstructured":"Brown DC, Boston RC, Farrar JT. Comparison of force plate gait analysis and owner assessment of pain using the canine brief pain inventory in dogs with osteoarthritis. J Vet Intern Med. 2013;27(1):22\u201330.","journal-title":"J Vet Intern Med"},{"key":"2110_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12917-015-0413-x","volume":"11","author":"BD Lascelles","year":"2015","unstructured":"Lascelles BD, Knazovicky D, Case B, Freire M, Innes JF, Drew AC, Gearing DP. A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Vet Res. 2015;11:101.","journal-title":"BMC Vet Res"},{"issue":"6","key":"2110_CR17","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/j.1939-1676.2011.00825.x","volume":"25","author":"BG Wernham","year":"2011","unstructured":"Wernham BG, Trumpatori B, Hash J, Lipsett J, Davidson G, Wackerow P, Thomson A, Lascelles BD. Dose reduction of meloxicam in dogs with osteoarthritis-associated pain and impaired mobility. J Vet Intern Med. 2011;25(6):1298\u2013305.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"2110_CR18","doi-asserted-by":"publisher","first-page":"e58125","DOI":"10.1371\/journal.pone.0058125","volume":"8","author":"MB Walton","year":"2013","unstructured":"Walton MB, Cowderoy E, Lascelles D, Innes JF. Evaluation of construct and criterion validity for the \u2018Liverpool Osteoarthritis in Dogs\u2019 (LOAD) clinical metrology instrument and comparison to two other instruments. PLoS One. 2013;8(3):e58125.","journal-title":"PLoS One"},{"issue":"4","key":"2110_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2460\/ajvr.69.4.486","volume":"69","author":"CJ LeBlanc","year":"2008","unstructured":"LeBlanc CJ, Horohov DW, Bauer JE, Hosgood G, Mauldin GE. Effects of dietary supplementation with fish oil on in vivo production of inflammatory mediators in clinically normal dogs. Am J Vet Res. 2008;69(4):486\u201393.","journal-title":"Am J Vet Res"},{"issue":"5","key":"2110_CR20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2460\/ajvr.2005.66.812","volume":"66","author":"JK Sessions","year":"2005","unstructured":"Sessions JK, Reynolds LR, Budsberg SC. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res. 2005;66(5):812\u20137.","journal-title":"Am J Vet Res"},{"issue":"3","key":"2110_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4102\/jsava.v80i3.198","volume":"80","author":"KE Joubert","year":"2009","unstructured":"Joubert KE. The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days. J S Afr Vet Assoc. 2009;80(3):179\u201384.","journal-title":"J S Afr Vet Assoc"},{"key":"2110_CR22","first-page":"501","volume-title":"Canine and feline nutrition","author":"L Case","year":"2011","unstructured":"Case L, Daristotle L, Hayek M, Raasch M. Osteoarthritis-a collective syndrome. In: Canine and feline nutrition. 3rd ed; 2011. p. 501\u201340.","edition":"3"},{"issue":"8","key":"2110_CR23","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2460\/javma.233.8.1278","volume":"233","author":"DC Brown","year":"2008","unstructured":"Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278\u201383.","journal-title":"J Am Vet Med Assoc"}],"updated-by":[{"DOI":"10.1186\/s12917-020-02713-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000}}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-019-2110-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T16:10:23Z","timestamp":1695312623000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-019-2110-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1186\/s12917-019-2110-7","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"23 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study procedures was approved by the Institutional Animal Care and Use Committee of the Faculty of Veterinary Medicine, Kasetsart University (ACKU61-VET-032). Informed, written consent was obtained from all owners prior to their dogs being entered in the study. Dogs remained in the care of their owners at home during and after the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BDXL and BB have provided continuing educational lectures sponsored by Pharmalink International. The other authors have no other conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"349"}}